<DOC>
	<DOCNO>NCT01642563</DOCNO>
	<brief_summary>Italian Platelet Technology Assessment Study ( IPTAS ) aim compare bleed frequency severity transfusion standard platelet versus platelet prepare two commercial pathogen reduction technology ( PRT ) perform proteomic analysis standard versus PRT platelet . The two technology analyze separately . Primary endpoint : incidence bleed grade 2 great recipient PRT platelet versus incidence recipient control ( standard ) platelet . Secondary endpoint : time first grade 2 great bleeding event first study transfusion ; proportion transfusion give treat breakthrough bleeding ; number day grade 2 great bleeding period platelet transfusion support ; number platelet unit transfuse total dose platelet transfuse per day thrombocytopenic platelet support ; proportion patient acute transfusion reaction ; post-transfusion platelet count increment Observational endpoint : frequency human leukocyte antigen ( HLA ) alloimmunization , frequency clinical refractoriness platelet transfusion demonstrate HLA alloimmunization , frequency clinical refractoriness platelet transfusion persistent period platelet support absence HLA human platelet antigen ( HPA ) alloimmunization Patients evaluate 4 week randomization .</brief_summary>
	<brief_title>Italian Platelet Technology Assessment Study</brief_title>
	<detailed_description>When patient 's platelet count , do early morning every day , fall 10000/microliter , physician charge issue platelet transfusion request transfusion service . Transfusion service ( know patient treatment arm ) issue PRT product standard product indicate , typically within hour request receipt ; patient 's physician identifies unit code intend recipient 's code determine vital sign ( pulse , blood pressure , body temp ) . Transfusion start complete 30 min . Adverse reaction monitor ward personnel day IPTAS local coordinator visit ward , check IPTAS patient ' record , fill IPTAS form , examines interview enrol patient transfer fill form data coordinate center Milan .</detailed_description>
	<criteria>1. adult ( &gt; 18 year ) 2. hematooncology diagnosis ( include patient newly diagnose previously diagnose ) 3. expect require 2 PLT transfusion 4 week 4. hospital admission ( patient admit outpatient clinic enrol ) 5. chemotherapy , relate match unrelated donor ( MUD ) transplant recipient 6. recurrent autotransplanted patient , require chemotherapy 7. negative pregnancy test female patient less 60 year old 1. presence HLA class I abs admission PRA &gt; 20 % 2. historical document record 2 1 hour postTX PLT correct count increment &lt; 5,000 per microliter 3. previously include IPTAS 4. diagnosis solid tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Platelet transfusion</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Transfusion transmissible infection</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Allogeneic hemopoietic stem cell transplant</keyword>
</DOC>